HLA Genotyping Supports a Nonautoimmune Etiology in Patients Diagnosed With Diabetes Under the Age of 6 Months

Children with permanent diabetes are usually assumed to have type 1 diabetes. It has recently been shown that there are genetic subgroups of diabetes that are often diagnosed during the neonatal period but may present later. A recent Italian study proposed that type 1 diabetes is rare before 6 months of age. We aimed to examine genetic susceptibility to type 1 diabetes in patients diagnosed with diabetes before the age of 2 years. We analyzed HLA class II genotypes, markers of autoimmune diabetes, in 187 children with permanent diabetes diagnosed at <2 years of age. Of the 79 subjects diagnosed at <6 months of age, 41% (95% CI 0.30–0.51) had type 1 diabetes–associated high-risk genotypes, a proportion similar to that in healthy population control subjects (44%, P = 0.56). This group included 32 patients with mutations in the KCNJ11 gene, which encodes Kir6.2 (44% high-risk HLA class II genotypes), and 47 in whom the etiology of diabetes was unknown (38% high-risk HLA class II genotypes). Of 108 patients diagnosed between 6 and 24 months of age, 93% (0.86–0.99) had high-risk HLA class II genotypes compared with 44% of the population control subjects (P < 0.0001). We conclude that infants diagnosed with diabetes before 6 months of age are unlikely to have autoimmune type 1 diabetes and are most likely to have a monogenic etiology.

[1]  F. Ashcroft,et al.  Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. , 2005, Diabetes.

[2]  Å. Lernmark,et al.  Diabetes-associated HLA genotypes affect birthweight in the general population , 2005, Diabetologia.

[3]  S. Ellard,et al.  The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation , 2005, Diabetologia.

[4]  A. Hattersley,et al.  High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. , 2005, Diabetes care.

[5]  A. Hattersley,et al.  KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes , 2005, Human mutation.

[6]  B. Glaser,et al.  Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. , 2004, The Journal of clinical endocrinology and metabolism.

[7]  A. Hattersley,et al.  Activating mutations in the KCNJ11 gene encoding the ATP-sensitive K+ channel subunit Kir6.2 are rare in clinically defined type 1 diabetes diagnosed before 2 years. , 2004, Diabetes.

[8]  A. Hattersley,et al.  Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. , 2004, Diabetes.

[9]  A. Hattersley,et al.  Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. , 2004, Diabetes.

[10]  A. Hattersley,et al.  Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[12]  A. Hattersley,et al.  Genetic cause of hyperglycaemia and response to treatment in diabetes , 2003, The Lancet.

[13]  A. Hattersley,et al.  Genetic Aetiology of Hyperglycaemia Alters Response to Treatment in Diabetes , 2003 .

[14]  M. Martinetti,et al.  Permanent diabetes mellitus in the first year of life , 2002, Diabetologia.

[15]  N. Keiding,et al.  Correlations between the incidence of childhood-onset Type I diabetes in Europe and HLA genotypes , 2001, Diabetologia.

[16]  A. Molven,et al.  Neonatal diabetes mellitus due to complete glucokinase deficiency. , 2001, The New England journal of medicine.

[17]  J. Shield Neonatal Diabetes: New Insights into Aetiology and Implications , 2000, Hormone Research in Paediatrics.

[18]  A. Hattersley,et al.  The fetal insulin hypothesis: an alternative explanation of the association of low bir thweight with diabetes and vascular disease , 1999, The Lancet.

[19]  P. Bingley,et al.  Prediction of IDDM in the General Population: Strategies Based on Combinations of Autoantibody Markers , 1997, Diabetes.

[20]  J. L. Botha,et al.  Diabetes diagnosed before the age of 2 years: mortality in a British cohort 8-17 years after onset. , 1992, International journal of epidemiology.

[21]  J. Todd,et al.  Regression mapping of association between the human leukocyte antigen region and Graves disease. , 2005, American journal of human genetics.

[22]  G. Eisenbarth,et al.  17. Immunologic endocrine disorders. , 2003, The Journal of allergy and clinical immunology.